{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0002117\nAge: 45\nGender: Female\nSample ID: P-0002117-T01-IM3\nGene Panel: IMPACT341\nCancer Type: Lung Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 40.0%\n=============\nDNA Variants:\nAR c.1250C>T (p.A417V) - in 14.00% of 329 reads\nARID2 c.234del (p.R80Efs*10) - in 19.00% of 597 reads\nATRX c.1079T>A (p.I360N) - in 54.00% of 1238 reads\nCDKN2A c.238C>T (p.R80*) - in 60.00% of 112 reads\nCHEK1 c.920C>T (p.S307F) - in 8.00% of 948 reads\nGATA2 c.322G>A (p.A108T) - in 35.00% of 361 reads\nTNFAIP3 c.404C>A (p.T135K) - in 18.00% of 455 reads\nCNA Data:\nMDM2 - High Level Amplification\nYES1 - High Level Amplification\nStructural Variants:\nCLIP4 - ALK (DELETION)\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Lung Adenocarcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Alectinib\",\n    \"Prior Treatment or Resistance Status\": \"ALK fusion positive (deletion in CLIP4 indicates ALK rearrangement)\",\n    \"Genomic Features\": \"ALK (deletion in CLIP4)\",\n    \"Link to FDA-approved Label\": \"https://www.fda.gov/drugs/resources-information-approved-drugs/alectinib\"\n  }\n}"
}